Navigation Links
Questcor Pharmaceuticals Expands Repurchase Program
Date:5/16/2012

, were driven by our belief that there is a substantial difference between the intrinsic value and the market value of our common stock.  This belief is based on several factors, including the following:

  • Net sales and earnings per share for the quarter ended March 31, 2012 increased by more than 60% over the quarter ended September 30, 2011 – the quarter prior to the initial expansion of our nephrotic syndrome sales force from 5 to 28 Acthar specialists;
  • We have gained greater confidence in the long-term potential for Acthar in the treatment of patients suffering from nephrotic syndrome;
  • We are in the process of further expanding our nephrology and neurology sales forces, and similar expansions in the past have resulted in significant growth in net sales; and
  • We are preparing to launch a pilot effort in rheumatology, a therapeutic area in which Acthar has a number of approved indications with sizeable markets with patients with high unmet needs.

From the beginning of 2008 through May 15, 2012, we have returned approximately 78% of our operating cash flow to shareholders by repurchasing stock at an average price of $12.26 per share.  During that period, we have also been able to fund other important initiatives, including the significant expansion of our research and development activities.  We have also continued our patient-support programs, providing $150 million in free Acthar through March 31, 2012. "

Stock repurchases under this program may be made through open market or privately negotiated transactions in accordance with all applicable laws, rules and regulations. The transactions may be made from time to time and in such amounts as management deems appropriate. The number of shares to be repurchased and the timing of repurchases will be based on several factors, including the price of the Company's common stock, general business and market condi
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
4. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
5. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
6. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
7. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
8. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
9. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
10. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
11. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has ... (SOFCs) - Global Strategic Business Report" report to their ... for Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The ... Canada , Europe , ... forecasts are provided for the period 2012 through 2020. Market ...
(Date:8/19/2014)... 2012, the European Union (EU) mandated use of the ICH-recommended ... – responding to the increasing need to understand and manage ... many regions, the main objectives of the PBRER are to:, ... of new or emerging information on the risks of a ... potential benefits of a drug; and , Allow ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
(Date:8/18/2014)... August 18, 2014 Global HIV Infection ... report announced by Reportstack. The rate of HIV infection and ... a declining note at a positive rate across the globe. ... 2.3 million in 2005 to 1.5 in 2013, with the ... for such drastic changes in the infection rates has been ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... are continually reaching new lows as they reduce the temperatures ... low enough to overcome the entropy (a measure of the ... discovery of exotic states of ultra-cold matter. Now physicists at ... out of a collection of atoms in much the same ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... Hardev Pandha of the Royal Surrey County Hospital, U.K., ... of Clinical Cancer Research. The paper is entitled "Synergistic ... Malignant Melanoma." , The research demonstrated that the innate ...
... , CAMBRIDGE, Mass., Sept. 24 Peptimmune, Inc. ... has formed a research and development collaboration with the Walter ... Research Center (NMRC), Silver Spring, MD to evaluate the Company,s ... dengue vaccines and point-of-care diagnostics. , , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial 2Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities 2
(Date:8/19/2014)... UK 19 August 2014: An engineer at the ... despite not having a brain to communicate with the ... Harvard, Professor L Mahadevan, has developed a mathematical model ... view of how these soft bodied animals get around. ... the central pattern generator (CPG) which states that the ...
(Date:8/19/2014)... to treat pain, but its effect on pain ... a recent study reported on the Neural ... rat models of an avulsion injury to the ... neuropathic pain) were given electroacupuncture stimulation at bilateral ... (GB34). After electroacupuncture therapy, chronic neuropathic pain in ...
(Date:8/19/2014)... exist in different forms, they have not been widely ... Now researchers from the University of Surrey and Trinity ... elastic bands with graphene, to create a flexible sensor ... be made cheaply. , Once treated, the rubber ... graphene - which imparts an electromechanical response on movement ...
Breaking Biology News(10 mins):Secrets of how worms wriggle uncovered 2
... by Professor Hans-Georg Kräusslich at Heidelberg University Hospitals, ... Tumor Virology of the Deutsches Krebsforschungszentrum (German Cancer ... label Human Immunodeficiency Viruses (HIV) for visual investigations ... , The labeling permits scientists to observe the ...
... bugs, according to Gilbert Waldbauer, whose book "Insights From Insects: ... (Prometheus Books). , "We know a lot about pests, because ... professor emeritus of entomology at the University of Illinois at ... 2 percent are considered pests. Just as some plants growing ...
... synthesis of QS-21A, a medicinally important molecule that helps ... at the University of Illinois at Urbana-Champaign. , In ... the body's immune response in vaccine therapies against aggressive ... prostate cancer, HIV-1 and malaria. An extract from the ...
Cached Biology News:Virologists make major step towards understanding the process of HIV infection 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 3
Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: